Wael Salameh, MD, Joins Biological Dynamics as Senior VP of Clinical Development

SAN DIEGO, Calif. -- Biological Dynamics, Inc., a molecular diagnostics company and a pioneer in the field of Alternating Current Electrokinetics (ACE)-based diagnostics, announced today the appointment of Wael Salameh, MD as VP of Clinical Development. In this role, Dr. Salameh will lead the efforts on analytical and clinical development of company's diagnostic portfolio.

“Biological Dynamics is poised to bring to the IVD market a very exciting and disruptive technology.  This unique platform has the potential to generate a number of assays that fill unmet clinical needs and impact the lives of thousands of patients in a variety of cancers and other diseases”, said Dr. Salameh. “I’m pleased to join the strong creative team at Biological Dynamics and to lead the efforts to develop assays meeting the highest clinical standards and to help maximize the full potential of the company."   

Dr. Salameh has extensive experience in developing and validating novel clinical diagnostic assays. Prior to joining Biological Dynamics in 2015, Dr. Salameh was VP of Clinical Development/Medical Affairs and CMO/CSO at both Clarus Therapeutics and Telome Sciences.

Dr. Salameh diagnostic development experience includes his work at Genentech as a Senior Medical Director and Leader for Companion Diagnostics and Biomarker Discovery in Early Drug Development and 5-years tenure as a Medical Director at Quest Diagnostics. At Quest, he was also responsible for developing and executing product strategy for company'sCardiovascular and Metabolic diagnostic products.

Dr. Salameh is board-certified in Internal Medicine, Endocrinology, Diabetes, and Metabolism, and is a Fellow of the American College of Physicians.

“We are thrilled to welcome Dr Salameh to our team,” said Raj Krishnan, CEO of Biological Dynamics. “He will be instrumental in our efforts to commercialize TRACE in the clinical markets and to educate the community on the benefits of improving the understanding of patient response to cancer therapies.”